FDA 新分析突出仿制药商之间更多的竞争与更低的仿制药价格相关
首页 > 资讯 > FDA 新分析突出仿制药商之间更多的竞争与更低的仿制药价格相关 出自识林
FDA 新分析突出仿制药商之间更多的竞争与更低的仿制药价格相关
笔记 2019-12-13 FDA New analysis highlights link between generic drug competition and lower drug prices, underscores importance of FDA efforts to spur generic drug development and market entry 新的分析突出了仿制药竞争与更低的药品价格之间的联系,强调了FDA努力促进仿制药开发和市场进入的重要性 The following quote is attributed to Acting FDA Commissioner Adm. Brett Giroir, M.D.: “Access to affordable medicines is a public health priority and bringing more drug competition to the market and addressing high costs are top priorities of the Administration, the Department of Health and Human Services and the FDA. “This new analysis underscores the critical nature of the work the FDA is undertaking to encourage timely market competition from high-quality, safe and effective generic drugs, which can help provide patients with access to affordable therapies that treat a wide range of medical conditions. “The FDA will continue to do all it can to support a robust, competitive generic drug market by helping facilitate a strong pipeline of applications, improving agency processes and providing industry with thoughtful, clear guidance and recommendations to support generic drug development and approval.” Related Information
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. |